Trade | Association for Accessible Medicines

Trade

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.

Highlights from the NAFTA 2.0 Congressional Briefing: The May 10 Amendments

On May 10, 2019, the Association for Accessible Medicines (AAM) hosted a briefing for congressional staff and other stakeholders on the twelfth anniversary of the May 10 Agreement, the bipartisan agreement to reopen the Colombia, Panama, Peru and South Korea trade agreements to address labor, environment and access to medicines issues.

The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It

The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars.

The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake. 

Read Full Brief

 

NAFTA 2.0: Obstacles to More Affordable Medicines

NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.

Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: 

Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

WASHINGTON DC (February 25, 2019) – Jonathan Kimball joins the Association for Accessible Medicines as Vice President, Trade and International Affairs, effective today.

“Jonathan will bring a wealth of government and industry advocacy experience to an area of increasing importance to AAM and our members,” said Jeff Francer, AAM’s Senior Vice President and General Counsel. “We are extremely lucky to have him on our team.”

AAM Statement on Signing of USMCA by President

WASHINGTON, DC (November 30, 2018) – AAM is extremely concerned that the USMCA, if left in its current form, will decrease prescription drug competition, inevitably leading to increased drug prices in the United States. This will harm American patients, job creators, workers and taxpayers. Furthermore, several provisions within the agreement are inconsistent with U.S. law and, if left unchanged, could lead to inappropriate changes in U.S.

Subscribe to Trade

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.